Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 2, 2025

OneStream Announces Leadership Updates

View original at finance.yahoo.com
OneStream Announces Leadership Updates OneStream initiates CFO transition plan, appoints new President to accelerate AI leadership, creates new Chief Accounting Officer role BIRMINGHAM, Mich., Dec…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Scott Leshinski's leadership as general manager of OneStream's AI business unit has been instrumental in advancing the company's portfolio of Finance AI products

    80% confidence
  • Industry data suggests demand for AI will increase, as Finance leaders expect to spend more on AI while cutting costs in other areas

    80% confidence
  • AI is now at the core of nearly everything OneStream does

    80% confidence
  • Bill Koefoed has been instrumental in the OneStream journey, providing strategic insight, rigor and a steady hand as they scaled the business and acclimated to the public markets

    80% confidence
  • Nearly a quarter of CFOs plan to increase overall AI spending by more than 50%

    80% confidence
  • John Kinzer brings extensive knowledge of OneStream and its financials, having served as Chair of the Board's Audit Committee since 2020, positioning him well to serve as Interim CFO

    80% confidence
  • Scott Leshinski will help capitalize on growth for purpose-built AI solutions and expand leadership position as AI solutions provider for the Office of the CFO

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com